UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION



WASHINGTON, D.C. 20580

October 19, 2006

Mark L. Kovner, Esq. Kirkland & Ellis, LLP 655 Fifteenth Street, N.W. Washington, DC 20005-5793 (202) 879-5200 (fax)

Re: In the Matter of Barr Pharmaceuticals, Inc., FTC Docket No. C-4171

Dear Mr. Kovner:

This letter notifies Barr Pharmaceuticals, Inc. that the Federal Trade Commission has approved the appointment of William Rahe as the Interim Monitor, and has approved the Interim Monitor Agreement by and among F. William Rahe and Barr Pharmaceuticals, Inc. dated October 5, 2006, pursuant to Paragraph III of the Order to Maintain Assets and, when made final, Paragraph V of the Decision and Order, issued in the above-referenced matter.

In according its approval, the Commission has relied upon the information submitted and representations made by Barr and has assumed them to be accurate and complete.

By direction of the Commission.

Donald S. Clark Secretary

cc: William Rahe
Quantic Regulatory Services, LLC
5 N. Regent Street, Suite 502
Livingston, NJ 07039
(973) 535-1734 (fax)

Frederick J. Killion General Counsel Barr Pharmaceuticals Inc. 400 Chestnut Ridge Road Woodcliff Lake, New Jersey 07677 (888) 843-0563 (fax)